Samaritan Pharmaceuticals Inc. (AMEX:LIV - News) a developer of innovative drugs, announced today, its subsidiary Samaritan Europe is accelerating SP01A’s, its lead HIV drug candidate, drug development timeline by initiating a late-stage Phase III trial in Europe before the end of its ongoing Phase II 28 day monotherapy study of SP-01A.
